GRFS (Grifols) Other Current Liabilities: $1,775 Mil (As of Mar. 2026)


GRFS Grifols SA GRFS
84 GF Score
Price $7.15
GF Value $8.92
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols Other Current Liabilities?

Grifols GRFS -2.52% 84 Other Current Liabilities is $1,775 Mil as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.92 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Grifols's other current liabilities for the quarter that ended in Mar. 2026 was $1,775 Mil.

Grifols's quarterly other current liabilities declined from Sep. 2025 ($2,529 Mil) to Dec. 2025 ($135 Mil) but then increased from Dec. 2025 ($135 Mil) to Mar. 2026 ($1,775 Mil).

Grifols's annual other current liabilities declined from Dec. 2023 ($99 Mil) to Dec. 2024 ($85 Mil) but then increased from Dec. 2024 ($85 Mil) to Dec. 2025 ($135 Mil).

Grifols Other Current Liabilities Related Terms

Grifols Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Grifols's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Other Current Liabilities Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.33 1,165.99 98.79 84.82 134.66

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 478.82 2,529.17 134.66 1,774.57
GRFS
84GF Score
Grifols SA GRFS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1,775 Mil mean?
Grifols (GRFS) has a Other Current Liabilities of $1,775 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Grifols.
Is Grifols' Other Current Liabilities too high?
Grifols' current Other Current Liabilities is $1,775 Mil. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Other Current Liabilities compare to LLY and JNJ?
Grifols' Other Current Liabilities of $1,775 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Grifols. Grifols's current Other Current Liabilities is $1,775 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.92, compared to a current price of $7.15 — trading 19.8% below its estimated fair value. The current Other Current Liabilities is $1,775 Mil. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Grifols (GRFS), the current Other Current Liabilities is $1,775 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.15 is trading 19.8% below its estimated GF Value™ of $8.92. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Other Current Liabilities: $1,775 Mil
  • GF Value™: $8.92 vs. price of $7.15 (19.8% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.15
Price
$8.92
GF Value